Boston Scientific Corporation (BSX): The stock had negative money flow to the tune of ($21.85 million) on Thursday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $19.61 million, whereas, the outflow of money on downticks was $41.46 million and the ratio between the two was 0.47. The block trade had a negative net money flow of ($23.97 million). The total block trade value undertaken on upticks was $2.34 million. On the other hand, downticks amounted to $26.31 million of the traded value, which shows distribution in the stock by traders. The ratio between uptick and downtick was 0.09. Boston Scientific Corporation (BSX) closed with marginal gains of 15 cents to end the day at $23.78, an increase of 0.63% over the previous days close. The stock recorded -0.5% for the week.
The stock has recorded a 20-day Moving Average of 3.07% and the 50-Day Moving Average is 4.71%. Shares have rallied 34.52% from its 1 Year high price. On Jul 11, 2016, the shares registered one year high at $23.99 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $22.89 and the 200 Day Moving Average price is recorded at $19.79.
Boston Scientific Corporation (NYSE:BSX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.79 and $23.66 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.86. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.78, notching a gain of 0.63% for the day. The total traded volume was 7,583,495 . The stock had closed at $23.63 on the previous day.
In an insider trading activity,The officer (EVP, GC & Chief Admin Officer) of Boston Scientific Corp, Pratt Timothy A. sold 24,000 shares at $23.39 on July 1, 2016. The Insider selling transaction had a total value worth of $561,360. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.